Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Separately, Maxim Group lifted their price target on shares of Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, March 31st.

Brainstorm Cell Therapeutics Stock Performance

BCLI opened at $2.85 on Friday. The stock has a market capitalization of $112.32 million, a PE ratio of -4.32 and a beta of -0.38. Brainstorm Cell Therapeutics has a one year low of $1.09 and a one year high of $4.70. The business’s 50 day moving average price is $2.54 and its 200 day moving average price is $2.15.

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) last announced its quarterly earnings results on Thursday, March 30th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. As a group, equities research analysts forecast that Brainstorm Cell Therapeutics will post -0.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BCLI. Tower Research Capital LLC TRC raised its holdings in shares of Brainstorm Cell Therapeutics by 739.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 8,862 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 7,806 shares during the period. Jane Street Group LLC purchased a new stake in Brainstorm Cell Therapeutics during the second quarter worth about $33,000. Raymond James Financial Services Advisors Inc. purchased a new stake in Brainstorm Cell Therapeutics during the first quarter worth about $37,000. XTX Topco Ltd acquired a new stake in shares of Brainstorm Cell Therapeutics during the first quarter worth about $40,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new position in shares of Brainstorm Cell Therapeutics in the first quarter valued at approximately $42,000. 10.61% of the stock is currently owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics

(Get Rating)

Brainstorm Cell Therapeutics, Inc is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer’s disease, and other neurodegenerative diseases.